En studie for å evaluere kjemoterapi med eller uten INCB161734 hos tidligere ubehandlede pasienter med KRAS G12D-mutert metastatisk pankreasduktalcarcinom (DAWN-303)
28. oktober 2026 oppdatert av: Incyte Corporation
En randomisert, dobbelblind, fase 3-studie av kjemoterapi med eller uten INCB161734 hos tidligere ubehandlede pasienter med metastatisk pankreatisk duktalt adenokarcinom med KRAS G12D-mutasjon (DAWN-303)
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Studieoversikt
Status
Status
Rekruttering
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Intervensjonell
Registrering (Antatt)
Registrering
588
Fase
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
Studiekontakt
- Navn: Incyte Corporation Call Center (US)
- Telefonnummer: 1.855.463.3463
- E-post: medinfo@incyte.com
Studer Kontakt Backup
- Navn: Incyte Corporation Call Center (ex-US)
- Telefonnummer: +800 00027423
- E-post: eumedinfo@incyte.com
Studiesteder
-
-
-
Canberra, Australia, 02605
- Har ikke rekruttert ennå
- Investigative Site AU002
-
Perth, Australia, 06009
- Rekruttering
- Investigative Site AU008
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 02109
- Har ikke rekruttert ennå
- Investigative Site AU011
-
-
Queensland
-
Chermside, Queensland, Australia, 04032
- Har ikke rekruttert ennå
- Investigative Site AU010
-
Townsville, Queensland, Australia, 04814
- Rekruttering
- Investigative Site AU009
-
-
South Australia
-
Woodville South, South Australia, Australia, 05011
- Rekruttering
- Investigative Site AU006
-
-
Victoria
-
Melbourne, Victoria, Australia, 03000
- Rekruttering
- Investigative Site AU004
-
Melbourne, Victoria, Australia, 03004
- Rekruttering
- Investigative Site AU001
-
Richmond, Victoria, Australia, 03121
- Rekruttering
- Investigative Site AU005
-
-
-
-
-
Anderlecht, Belgia, 01070
- Har ikke rekruttert ennå
- Investigative Site BE008
-
Brussels, Belgia, 01090
- Rekruttering
- Investigative Site BE003
-
Brussels, Belgia, 01200
- Rekruttering
- Investigative Site BE009
-
Edegem, Belgia, 02650
- Rekruttering
- Investigative Site BE001
-
Ghent, Belgia, 09000
- Rekruttering
- Investigative Site BE005
-
Gilly, Belgia, 06060
- Rekruttering
- Investigative Site BE007
-
Leuven, Belgia, 03000
- Rekruttering
- Investigative Site BE004
-
Liège, Belgia, 04000
- Har ikke rekruttert ennå
- Investigative Site BE006
-
Yvoir, Belgia, 05530
- Har ikke rekruttert ennå
- Investigative Site BE002
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V5C2
- Har ikke rekruttert ennå
- Investigative Site CA007
-
Kingston, Ontario, Canada, K7L 5P9
- Har ikke rekruttert ennå
- Investigative Site CA008
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Investigative Site CA001
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Rekruttering
- Investigative Site CA006
-
Québec, Quebec, Canada, G1J 1Z4
- Rekruttering
- Investigative Site CA004
-
-
-
-
-
Aalborg, Danmark, 09000
- Har ikke rekruttert ennå
- Investigative Site DK006
-
Herlev, Danmark, 02730
- Har ikke rekruttert ennå
- Investigative Site DK001
-
Køge, Danmark, 04600
- Har ikke rekruttert ennå
- Investigative Site DK003
-
Odense C, Danmark, 05000
- Har ikke rekruttert ennå
- Investigative Site DK004
-
Vejle, Danmark, 07100
- Har ikke rekruttert ennå
- Investigative Site DK002
-
Århus N, Danmark, 08200
- Rekruttering
- Investigative Site DK005
-
-
-
-
-
HUS, Finland, 00290
- Rekruttering
- Investigative Site FI001
-
Tampere, Finland, 33521
- Rekruttering
- Investigative Site FI003
-
Turku, Finland, 20521
- Har ikke rekruttert ennå
- Investigative Site FI002
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Har ikke rekruttert ennå
- Investigative Site US058
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Rekruttering
- Investigative Site US016
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85224
- Rekruttering
- Investigative Site US026
-
Tucson, Arizona, Forente stater, 85719
- Har ikke rekruttert ennå
- Investigative Site US045
-
-
California
-
Duarte, California, Forente stater, 91010
- Rekruttering
- Investigative Site US051
-
Fullerton, California, Forente stater, 92835
- Har ikke rekruttert ennå
- Investigative Site US085
-
La Jolla, California, Forente stater, 92093
- Har ikke rekruttert ennå
- Investigative Site US054
-
Long Beach, California, Forente stater, 90806-1650
- Har ikke rekruttert ennå
- Investigative Site US086
-
Los Angeles, California, Forente stater, 90089
- Rekruttering
- Investigative Site US036
-
Los Angeles, California, Forente stater, 90027
- Rekruttering
- Investigative Site US027
-
Los Angeles, California, Forente stater, 91204-3640
- Rekruttering
- Investigative Site US048
-
Orange, California, Forente stater, 92868
- Rekruttering
- Investigative Site US049
-
San Francisco, California, Forente stater, 94143
- Rekruttering
- Investigative Site US034
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- Investigative Site US001
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Investigative Site US071
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- Har ikke rekruttert ennå
- Investigative Site US013
-
Washington D.C., District of Columbia, Forente stater, 20016
- Har ikke rekruttert ennå
- Investigative Site US046
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33901
- Rekruttering
- Investigative Site US072
-
Jacksonville, Florida, Forente stater, 32207
- Har ikke rekruttert ennå
- Investigative Site US083
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- Investigative Site US075
-
St. Petersburg, Florida, Forente stater, 33701-4553
- Rekruttering
- Investigative Site US074
-
West Palm Beach, Florida, Forente stater, 33401
- Rekruttering
- Investigative Site US073
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Investigative Site US023
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Har ikke rekruttert ennå
- Investigative Site US079
-
Evanston, Illinois, Forente stater, 60201
- Rekruttering
- Investigative Site US030
-
Naperville, Illinois, Forente stater, 60540
- Rekruttering
- Investigative Site US005
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Investigative Site US009
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46250
- Har ikke rekruttert ennå
- Investigative Site US021
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70121
- Rekruttering
- Investigative Site US007
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Investigative Site US022
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109-9001
- Har ikke rekruttert ennå
- Investigative Site US006
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Investigative Site US010
-
Grand Rapids, Michigan, Forente stater, 49503
- Rekruttering
- Investigative Site US078
-
Ypsilanti, Michigan, Forente stater, 48197
- Har ikke rekruttert ennå
- Investigative Site US012
-
-
Minnesota
-
Maple Grove, Minnesota, Forente stater, 55369
- Rekruttering
- Investigative Site US066
-
-
Mississippi
-
Hattiesburg, Mississippi, Forente stater, 39401
- Har ikke rekruttert ennå
- Investigative Site US047
-
-
Nevada
-
Reno, Nevada, Forente stater, 89502
- Har ikke rekruttert ennå
- Investigative Site US084
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- Investigative Site US077
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Investigative Site US017
-
-
New York
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- Investigative Site US059
-
New York, New York, Forente stater, 10065
- Rekruttering
- Investigative Site US003
-
New York, New York, Forente stater, 10016
- Rekruttering
- Investigative Site US031
-
New York, New York, Forente stater, 10128
- Rekruttering
- Investigative Site US041
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Investigative Site US029
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- Investigative Site US035
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Investigative Site US020
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- Investigative Site US050
-
Columbus, Ohio, Forente stater, 43210
- Har ikke rekruttert ennå
- Investigative Site US033
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Har ikke rekruttert ennå
- Investigative Site US042
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Investigative Site US008
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Rekruttering
- Investigative Site US043
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Rekruttering
- Investigative Site US056
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Har ikke rekruttert ennå
- Investigative Site US082
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57105-2140
- Rekruttering
- Investigative Site US055
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Investigative Site US060
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Investigative Site US039
-
Nashville, Tennessee, Forente stater, 37232-6309
- Rekruttering
- Investigative Site US070
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Investigative Site US067
-
Denison, Texas, Forente stater, 75020
- Rekruttering
- Investigative Site US062
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Investigative Site US011
-
San Antonio, Texas, Forente stater, 78240
- Rekruttering
- Investigative Site US063
-
San Antonio, Texas, Forente stater, 78229
- Har ikke rekruttert ennå
- Investigative Site US080
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Rekruttering
- Investigative Site US053
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Har ikke rekruttert ennå
- Investigative Site US057
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Investigative Site US065
-
Salem, Virginia, Forente stater, 24153
- Rekruttering
- Investigative Site US064
-
-
Washington
-
Olympia, Washington, Forente stater, 98506
- Rekruttering
- Investigative Site US081
-
Seattle, Washington, Forente stater, 98104
- Rekruttering
- Investigative Site US032
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- Rekruttering
- Investigative Site US044
-
-
-
-
-
Brest, Frankrike, 29200
- Har ikke rekruttert ennå
- Investigative Site FR013
-
Dijon, Frankrike, 21000
- Har ikke rekruttert ennå
- Investigative Site FR014
-
Lille, Frankrike, 59037
- Har ikke rekruttert ennå
- Investigative Site FR002
-
Lyon, Frankrike, 69008
- Har ikke rekruttert ennå
- Investigative Site FR011
-
Lyon, Frankrike, 69373
- Har ikke rekruttert ennå
- Investigative Site FR016
-
Marseille, Frankrike, 13385
- Har ikke rekruttert ennå
- Investigative Site FR006
-
Montpellier, Frankrike, 34298
- Har ikke rekruttert ennå
- Investigative Site FR015
-
Paris, Frankrike, 75013
- Har ikke rekruttert ennå
- Investigative Site FR003
-
Paris, Frankrike, 75015
- Har ikke rekruttert ennå
- Investigative Site FR009
-
Pessac, Frankrike, 33604
- Har ikke rekruttert ennå
- Investigative Site FR004
-
Poitiers, Frankrike, 86021
- Har ikke rekruttert ennå
- Investigative Site FR008
-
Reims, Frankrike, 51100
- Rekruttering
- Investigative Site FR010
-
Rennes, Frankrike, 35042
- Rekruttering
- Investigative Site FR005
-
Toulouse, Frankrike, 31059
- Har ikke rekruttert ennå
- Investigative Site FR007
-
Tours, Frankrike, 37000
- Har ikke rekruttert ennå
- Investigative Site FR012
-
Villejuif, Frankrike, 94805
- Har ikke rekruttert ennå
- Investigative Site FR001
-
-
-
-
-
Batumi, Georgia, 06004
- Har ikke rekruttert ennå
- Investigative Site GE004
-
Marneuli, Georgia, 03000
- Har ikke rekruttert ennå
- Investigative Site GE002
-
Tbilisi, Georgia, 00112
- Har ikke rekruttert ennå
- Investigative Site GE005
-
Tbilisi, Georgia, 00159
- Har ikke rekruttert ennå
- Investigative Site GE006
-
Tbilisi, Georgia, 00186
- Har ikke rekruttert ennå
- Investigative Site GE001
-
Tbilisi, Georgia, 00186
- Har ikke rekruttert ennå
- Investigative Site GE003
-
-
-
-
-
Bologna, Italia, 40138
- Har ikke rekruttert ennå
- Investigative Site IT002
-
Brescia, Italia, 25124
- Rekruttering
- Investigative Site IT010
-
Candiolo, Italia, 10060
- Rekruttering
- Investigative Site IT009
-
Foggia, Italia, 71122
- Har ikke rekruttert ennå
- Investigative Site IT012
-
Milan, Italia, 20133
- Har ikke rekruttert ennå
- Investigative Site IT008
-
Milan, Italia, 20132
- Rekruttering
- Investigative Site IT006
-
Naples, Italia, 80131
- Har ikke rekruttert ennå
- Investigative Site IT011
-
Pisa, Italia, 56126
- Har ikke rekruttert ennå
- Investigative Site IT003
-
Roma, Italia, 00152
- Rekruttering
- Investigative Site IT004
-
Rome, Italia, 00138
- Har ikke rekruttert ennå
- Investigative Site IT005
-
Rozzano, Italia, 20089
- Rekruttering
- Investigative Site IT001
-
Verona, Italia, 37134
- Rekruttering
- Investigative Site IT007
-
-
-
-
-
Akashi, HYGO, Japan, 673-0021
- Aktiv, ikke rekrutterende
- Investigative Site JP015
-
Fukuoka Fukuoka, Japan, 812-0054
- Har ikke rekruttert ennå
- Investigative Site JP012
-
Kahoku-gun, Japan, 920-0293
- Rekruttering
- Investigative Site JP010
-
Kitaadachi-gun, Japan, 362-0806
- Har ikke rekruttert ennå
- Investigative Site JP014
-
Kōtoku, Japan, 135-8550
- Rekruttering
- Investigative Site JP003
-
Mitaka-shi, Japan, 181-8611
- Rekruttering
- Investigative Site JP007
-
Osaka, Japan, 541-8567
- Rekruttering
- Investigative Site JP004
-
Sapporo Hokkaido, Japan, 060-0814
- Har ikke rekruttert ennå
- Investigative Site JP011
-
Shinjuku-ku, Japan, 160-0023
- Rekruttering
- Investigative Site JP009
-
Suita, Osaka, Japan, 565-0871
- Har ikke rekruttert ennå
- Investigative Site JP013
-
Toyama, Japan, 930-0194
- Rekruttering
- Investigative Site JP006
-
Wakayama, Japan, 641-8510
- Rekruttering
- Investigative Site JP008
-
Yokohama, Japan, 241-8515
- Rekruttering
- Investigative Site JP001
-
-
-
-
-
Amsterdam, Nederland, 1081 HV
- Rekruttering
- Investigative Site NL001
-
Eindhoven, Nederland, 5623 EJ
- Rekruttering
- Investigative Site NL007
-
Groningen, Nederland, 9700 RB
- Rekruttering
- Investigative Site NL005
-
Maastricht, Nederland, 6229 HX
- Rekruttering
- Investigative Site NL003
-
Utrecht, Nederland, 3543 AZ
- Rekruttering
- Investigative Site NL006
-
-
-
-
-
Auckland, New Zealand, 01023
- Har ikke rekruttert ennå
- Investigative Site NZ001
-
-
-
-
-
Bergen, Norge, 05021
- Rekruttering
- Investigative Site NO002
-
Oslo, Norge, 00379
- Rekruttering
- Investigative Site NO001
-
Stavanger, Norge, 04011
- Har ikke rekruttert ennå
- Investigative Site NO005
-
Trondheim, Norge, 07030
- Har ikke rekruttert ennå
- Investigative Site NO003
-
-
-
-
-
Gdansk, Polen, 80-214
- Har ikke rekruttert ennå
- Investigative Site PL008
-
Krakow, Polen, 31-501
- Har ikke rekruttert ennå
- Investigative Site PL003
-
Warsaw, Polen, 02-507
- Har ikke rekruttert ennå
- Investigative Site PL002
-
Warsaw, Polen, 01-748
- Rekruttering
- Investigative Site PL007
-
Warsaw, Polen, 02-034
- Rekruttering
- Investigative Site PL001
-
Wroclaw, Polen, 53-439
- Har ikke rekruttert ennå
- Investigative Site PL004
-
-
-
-
-
Dorado, Puerto Rico, 00646
- Rekruttering
- Investigative Site PR001
-
-
-
-
-
Badalona, Spania, 08916
- Har ikke rekruttert ennå
- Investigative Site ES011
-
Barcelona, Spania, 08035
- Har ikke rekruttert ennå
- Investigative Site ES003
-
Barcelona, Spania, 08011
- Rekruttering
- Investigative Site ES002
-
Las Palmas de Gran Canaria, Spania, 35016
- Rekruttering
- Investigative Site ES014
-
Madrid, Spania, 28041
- Rekruttering
- Investigative Site ES008
-
Madrid, Spania, 28034
- Har ikke rekruttert ennå
- Investigative Site ES006
-
Madrid, Spania, 28040
- Har ikke rekruttert ennå
- Investigative Site ES012
-
Madrid, Spania, 28009
- Rekruttering
- Investigative Site ES016
-
Madrid, Spania, 28040
- Rekruttering
- Investigative Site ES007
-
Madrid, Spania, 28050
- Rekruttering
- Investigative Site ES013
-
Palma de Mallorca, Spania, 07120
- Har ikke rekruttert ennå
- Investigative Site ES005
-
Santander, Spania, 39008
- Rekruttering
- Investigative Site ES009
-
Seville, Spania, 41009
- Har ikke rekruttert ennå
- Investigative Site ES010
-
Valencia, Spania, 46009
- Har ikke rekruttert ennå
- Investigative Site ES015
-
Valencia, Spania, 46010
- Har ikke rekruttert ennå
- Investigative Site ES017
-
Valencia, Spania, 46014
- Rekruttering
- Investigative Site ES001
-
Zaragoza, Spania, 50009
- Rekruttering
- Investigative Site ES004
-
-
-
-
-
Dundee, Storbritannia, DD1 9SY
- Rekruttering
- Investigative Site GR008
-
Guildford, Storbritannia, GU2 7XX
- Har ikke rekruttert ennå
- Investigative Site GB011
-
Headington, Storbritannia, OX3 7LE
- Har ikke rekruttert ennå
- Investigative Site GB002
-
Leeds, Storbritannia, LS9 7TF
- Har ikke rekruttert ennå
- Investigative Site GB001
-
London, Storbritannia, NW3 2QG
- Har ikke rekruttert ennå
- Investigative Site GB004
-
London, Storbritannia, EC1A 7BE
- Rekruttering
- Investigative Site GB009
-
Manchester, Storbritannia, M20 4BX
- Har ikke rekruttert ennå
- Investigative Site GB003
-
Northwood, Storbritannia, HA6 2RN
- Har ikke rekruttert ennå
- Investigative Site GB010
-
Norwich, Storbritannia, NR4 7UY
- Har ikke rekruttert ennå
- Investigative Site GB005
-
-
-
-
-
Basel, Sveits, 04058
- Rekruttering
- Investigative Site CH005
-
Bern, Sveits, 03010
- Har ikke rekruttert ennå
- Investigative Site CH003
-
Geneva, Sveits, 01205
- Har ikke rekruttert ennå
- Investigative Site CH004
-
Lausanne, Sveits, 01011
- Rekruttering
- Investigative Site CH002
-
Zurich, Sveits, 08091
- Rekruttering
- Investigative Site CH001
-
-
-
-
-
Linköping, Sverige, 58185
- Har ikke rekruttert ennå
- Investigative Site SE003
-
Lund, Sverige, 222 42
- Rekruttering
- Investigative Site SE001
-
Stockholm, Sverige, 17176
- Rekruttering
- Investigative Site SE002
-
-
-
-
-
Goyang-si, Sør -Korea, 10408
- Rekruttering
- Investigative Site KR004
-
Seongnam-si, Sør -Korea, 13496
- Rekruttering
- Investigative Site KR007
-
Seongnam-si, Sør -Korea, 13620
- Rekruttering
- Investigative Site KR005
-
Seoul, Sør -Korea, 06591
- Har ikke rekruttert ennå
- Investigative Site KR008
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Investigative Site KR002
-
Seoul, Sør -Korea, 05505
- Rekruttering
- Investigative Site KR001
-
Seoul, Sør -Korea, 03722
- Rekruttering
- Investigative Site KR006
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Investigative Site KR003
-
-
-
-
-
Berlin, Tyskland, 10365
- Har ikke rekruttert ennå
- Investigative Site DE018
-
Berlin, Tyskland, 13353
- Rekruttering
- Investigative Site DE020
-
Bochum, Tyskland, 44791
- Rekruttering
- Investigative Site DE003
-
Bonn, Tyskland, 53127
- Har ikke rekruttert ennå
- Investigative Site DE019
-
Cologne, Tyskland, D-50937
- Rekruttering
- Investigative Site DE008
-
Dresden, Tyskland, 01307
- Har ikke rekruttert ennå
- Investigative Site DE001
-
Düsseldorf, Tyskland, 40225
- Har ikke rekruttert ennå
- Investigative Site DE013
-
Essen, Tyskland, 45147
- Rekruttering
- Investigative Site DE004
-
Frankfurt, Tyskland, 60488
- Rekruttering
- Investigative Site DE005
-
Freiburg im Breisgau, Tyskland, 79106
- Rekruttering
- Investigative Site DE016
-
Göttingen, Tyskland, 37075
- Har ikke rekruttert ennå
- Investigative Site DE017
-
Halle, Tyskland, 06120
- Har ikke rekruttert ennå
- Investigative Site DE002
-
Hamburg, Tyskland, 20251
- Rekruttering
- Investigative Site DE007
-
Hamburg, Tyskland, 22763
- Rekruttering
- Investigative Site DE006
-
Leipzig, Tyskland, 04103
- Har ikke rekruttert ennå
- Investigative Site DE009
-
Munich, Tyskland, 81377
- Har ikke rekruttert ennå
- Investigative Site DE015
-
München, Tyskland, 81737
- Rekruttering
- Investigative Site DE014
-
Nuremberg, Tyskland, 90419
- Rekruttering
- Investigative Site DE010
-
Ulm, Tyskland, 89081
- Rekruttering
- Investigative Site DE011
-
-
-
-
-
Graz, Østerrike, 8036
- Har ikke rekruttert ennå
- Investigative Site AT005
-
Innsbruck, Østerrike, 06020
- Rekruttering
- Investigative Site AT002
-
Linz, Østerrike, 04010
- Rekruttering
- Investigative Site AT004
-
Salzburg, Østerrike, 05020
- Rekruttering
- Investigative Site AT003
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation
- No prior systemic treatment in the metastatic setting
- ECOG Performance status 0-1
- Adequate organ function
Exclusion Criteria:
- Prior treatment with any KRAS inhibitor
- Chronic or current active infection requiring systemic treatment within 1 week prior to the first dose of study drug
- Known active CNS metastases
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
2
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: INCB161734 plus chemotherapy
INCB161734 at the protocol-defined dose with investigator's choice of chemotherapy (mFOLFIRINOX or GemNabP) in accordance with the protocol-defined requirements. |
Oral; tablet The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:
Andre navn:
|
|
Eksperimentell: Placebo plus chemotherapy
Placebo at the protocol-defined dose with investigator's choice of chemotherapy (mFOLFIRINOX or GemNabP) in accordance with the protocol-defined requirements. |
The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:
Andre navn:
Oral; tablet |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: Up to approximately 3 years
|
Defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 3 years
|
|
Progression-free survival (PFS) by BICR
Tidsramme: Up to approximately 2 years
|
Defined as the time from the date of randomization to the date of the first documented progression as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause. |
Up to approximately 2 years
|
|
Objective Response by BICR
Tidsramme: Up to approximately 2 years
|
Defined as complete response (CR) or partial response (PR) as determined by BICR per RECIST v1.1. |
Up to approximately 2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of Response (DOR) by BICR
Tidsramme: Up to approximately 2 years
|
Defined as the time from the earliest date of documented response until the earliest date of disease progression as determined by BICR per RECIST v1.1 or death from any cause. |
Up to approximately 2 years
|
|
Disease control by BICR
Tidsramme: Up to approximately 2 years
|
Defined as having CR, PR, or stable disease (SD) as the best response determined by BICR per RECIST v1.1. |
Up to approximately 2 years
|
|
Progression-Free Survival (PFS) by investigator assessment
Tidsramme: Up to approximately 2 years
|
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per RECIST v1.1 or death due to any cause. |
Up to approximately 2 years
|
|
Objective response by investigator assessment
Tidsramme: Up to approximately 2 years
|
Defined as CR or PR as determined by the investigator per RECIST v1.1. |
Up to approximately 2 years
|
|
DOR by investigator assessment
Tidsramme: Up to approximately 2 years
|
Defined as the time from the earliest date of documented response until earliest date of disease progression as determined by the investigator per RECIST v1.1 or death from any cause. |
Up to approximately 2 years
|
|
Disease control by investigator assessment
Tidsramme: Up to approximately 2 years
|
Defined as having CR, PR, or SD as the best response as determined by the investigator per RECIST v1.1. |
Up to approximately 2 years
|
|
Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Up to approximately 2 years and 30 days
|
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug until 30 days after the last dose of study drug or the start of new anticancer therapy, whichever occurs first. |
Up to approximately 2 years and 30 days
|
|
TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment
Tidsramme: Up to approximately 2 years and 30 days
|
TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment. |
Up to approximately 2 years and 30 days
|
|
Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 (C30) at each postbaseline visit
Tidsramme: Up to approximately 2 years
|
The EORTC QLQ-C30 is a validated, self-administered questionnaire developed to assess the quality of life in cancer patients. It consists of 30 questions divided into several subscales, including 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and a number of single-item measures that assess additional symptoms such as dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. |
Up to approximately 2 years
|
|
Change from baseline in EORTC QLQ-PAN26 score at each postbaseline visit
Tidsramme: Up to approximately 2 years
|
The EORTC QLQ-PAN26 consists of 26 questions that assess 9 pancreatic cancer-related and treatment-related symptoms (pain, eating-related items, cachexia, hepatic symptoms, side effects, altered bowel habits, ascites, indigestion, and flatulence) and 5 emotional domains specific to pancreatic cancer (body image, healthcare satisfaction, sexuality, fear of future health, and ability to plan for the future). The QLQ-PAN26 is scored on a 4-point scale that ranges from not at all to very much. |
Up to approximately 2 years
|
|
Change from baseline in EQ-5D-5L score at each postbaseline visit
Tidsramme: Up to approximately 2 years
|
The EQ-5D-5L is a validated, self-reported instrument for assessing HRQoL across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels of severity, ranging from no problems to extreme problems. The questionnaire also includes a visual analog scale for self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health). |
Up to approximately 2 years
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Studieleder: Incyte Medical Monitor, Incyte Corporation
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
9. april 2026
Primær fullføring (Antatt)
Primær fullføring
15. september 2028
Studiet fullført (Antatt)
Studiet fullført
19. mars 2029
Datoer for studieregistrering
Først innsendt
Først innsendt
3. april 2026
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
3. april 2026
Først lagt ut (Faktiske)
Først lagt ut
13. april 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
30. oktober 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
28. oktober 2026
Sist bekreftet
Sist bekreftet
1. oktober 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- INCB161734-303
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD-delingstidsramme
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Tilgangskriterier for IPD-deling
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .